Deferasirox治疗铁质积聚的疗效如何呢？

It is currently the only oral iron chelator developed by Novartis. It was approved by the FDA in November 2005 for use in patients 2 years and older with chronic iron overload caused by blood transfusions.

In December 2012, Deferasirox was approved by the European Commission for the treatment of chronic iron overload in patients aged 10 years and above with non-transfusion-dependent thalassemia (NTDT) syndrome who require chelation therapy due to contraindications or insufficiency of deferoxamine mesylate therapy.

On January 23, 2013, the FDA approved a new indication for deferasirox for the treatment of chronic iron overload in patients aged 10 years and older with non-transfusion-dependent thalassemia (NTDT).

So, how effective is Deferasirox in treating iron buildup?

Therapeutic benefits of Deferasirox for treating iron accumulation:

To explore the clinical efficacy of Deferasirox, deferiprone and deferoxamine in the treatment of iron load in patients with thalassemia major.

Fifty patients with iron overload in the heart and liver detected by MRI T2 technology were randomly divided into deferoxamine treatment (DFO) group (18 cases), deferiprone treatment (DFP) group (22 cases), and Deferasirox treatment (DFX) group (10 cases). The baseline data of patients in the three groups at admission, pre- and post-treatment serum ferritin (SF) values, cardiac MRI T2 values, and liver MRI were statistically analyzed. Changes in T2 values. Results: There was no statistically significant difference in serum SF values between the 3 groups (F=3.089, P>0.05); there was no statistically significant difference in liver MRI T2 values among the 3 groups (F=0.131, P>0.05); there was a statistically significant difference in cardiac iron load MRI T2 values among the 3 groups [(34.27 ±6.30), (23.0±2.79), (21.8±2.20) ms; F=39.54, P<0.05].

Conclusion: Both deferoxamine and deferiprone can effectively relieve iron load in patients with thalassemia major. Among them, deferiprone is more effective in treating cardiac iron overload in patients with thalassemia than deferoxamine and Deferasirox, and is worthy of clinical promotion.